SCHEMBL1883207

SCHEMBL1883207

COc1cc(Cl)ccc1C(N)=O.COc1ccccc1N1CCN(c2ccc(S(=O)(=O)O)cn2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.49
LMNA P02545 5/20 0.46
MAPT P10636 4/20 0.46
POLB P06746 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NOD2 Q9HC29 1/20 0.46
TP53 P04637 2/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 1/20 0.45
MAPK1 P28482 2/20 0.45
USP2 O75604 1/20 0.45
GLA P06280 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884480 0.90 TSHR (0.46) RPS6KB1LMNAMAPTPOLBKDM4E
SCHEMBL1881342 0.90 RPS6KB1 (0.45) RPS6KB1LMNAMAPTPOLBKDM4E
SCHEMBL4370313 0.89 FLT1 (0.43) MAPTKDM4ESMN1; SMN2GAATSHR
SCHEMBL4370237 0.88 KMT2A (0.43) MAPTKDM4ESMN1; SMN2GAAHSD17B10
SCHEMBL1883232 0.88 ALDH1A1 (0.48) RPS6KB1LMNAMAPTPOLBHTT
SCHEMBL1891647 0.87 LMNA (0.48) RPS6KB1LMNAMAPTSMN1; SMN2GLA
SCHEMBL4371955 0.86 FLT1 (0.41) KDM4ETSHRALDH1A1CYP1A2CYP2C9
SCHEMBL4374520 0.85 CA12 (0.43) MAPTKDM4ETP53ALDH1A1CYP1A2
SCHEMBL1883205 0.85 FLT1 (0.58) LMNAMAPTPOLBKDM4EHTT
SCHEMBL4370393 0.85 CA12 (0.42) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US claimed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US claimed
US-7939532-B2 Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2011-05-10 US disclosed
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292247-A1 HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS STS, TPMT, DPYD RPS6KB1 536/4885LMNA 1709/4885MAPT 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.